SEARCH

SEARCH BY CITATION

References

  • 1
    Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999;84:18979.
  • 2
    Solomon CG. The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks. Endocrinol Metab Clin North Am 1999;28:24763.
  • 3
    Kitzinger C, Willmott J. “The thief of womanhood”: women's experience of polycystic ovarian syndrome. Soc Sci Med 2002;54:34961.
  • 4
    Snyder BS. The lived experience of women diagnosed with polycystic ovary syndrome. J Obstet Gynecol Neonatal Nurs 2006;35:38592.
  • 5
    Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:27459.
  • 6
    Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000;132:98993.
  • 7
    The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:417.
  • 8
    Balen A, Homburg R, Franks S. Defining polycystic ovary syndrome. BMJ 2009;338:a2968.
  • 9
    Bradley C. Measuring quality of life in diabetes. Diabetes Annual 1996;10:20724.
  • 10
    Muldoon MF, Barger SD, Flory JD, Manuck SB. What are quality of life measurements measuring? BMJ 1998;316:5425.
  • 11
    Holmes S. Assessing the quality of life—reality or impossible dream?: A discussion paper. Int J Nurs Stud 2005;42:493501.
  • 12
    Speight J, Shaw JAM. Does one size really fit all? Only by considering individual preferences and priorities will the true impact of insulin pump therapy on quality of life be determined. Diabet Med 2007;24:6935.
  • 13
    Bradley C. Importance of differentiating health status from quality of life. Lancet 2001;357:78.
  • 14
    Jones GL, Hall JM, Balen AH, Ledger WL. Health-related quality of life measurement in women with polycystic ovary syndrome: A systematic review. Hum Reprod Update 2008;14:1525.
  • 15
    European Medicines Agency (EMEA). Reflection paper on the regulatory guidance for the use of heath-related quality of life (HRQL) measures in the evaluation of medicinal products. 2004. Available from: http://www.ema.europa.eu/pdfs/human/ewp/13939104en.pdf Accessed 28, 2010.
  • 16
    US Department of Health and Human Services FDA Center for Drug Evaluation and Research, US Department of Health and Human Services FDA Center for Biologics Evaluation and Research, US Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for Industry: Patient Report Outcome Measures: Use in clinical medical product development to support labelling claims: draft guidance. HQLO 2006;4.
  • 17
    Speight J, McCann M. Assessing the individualised impact of polycystic ovary syndrome (PCOS) on women's quality of life using the SEIQoL. Proceedings of the British Psychological Society 2006;15(1).
  • 18
    Cronin L, Guyatt G, Griffith L, et al. Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 1998;83:197687.
  • 19
    Trent ME, Rich M, Bryn Austin S, Gordon CM. Quality of life in adolescent girls with polycystic ovary syndrome. Arch Pediatr Adolesc Med 2002;156:55660.
  • 20
    Elsenbruch S, Hahn S, Kowalsky D, et al. Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:58017.
  • 21
    Trent ME, Rich M, Austin SB, Gordon CM. Fertility concerns and sexual behavior in adolescent girls with polycystic ovary syndrome: Implications for quality of life. J Pediatr Adolesc Gynecol 2003;16:337.
  • 22
    Guyatt G, Weaver B, Cronin L, et al. Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated. J Clin Epidemiol 2004;57:127987.
  • 23
    Isoppo C, Fiori E, Valeriano R, et al. Clinical-psychological and psychophysiological assessment in women with obesity and Polycystic Ovary Syndrome (PCOS). Psychol Health 2004;19(Suppl. 1):86.
  • 24
    Jones GL, Benes K, Clark TL, et al. The Polycystic Ovary Syndrome Health-Related Quality of Life Questionnaire (PCOSQ): a validation. Hum Reprod 2004;19:3717.
  • 25
    Schmid J, Kirchengast S, Vytiska-Binstorfer E, Huber J. Infertility caused by PCOS—health-related quality of life among Austrian and Moslem immigrant women in Austria. Hum Reprod 2004;19:22517.
  • 26
    Clayton WJ, Lipton M, Elford J, et al. A randomized controlled trial of laser treatment among hirsute women with polycystic ovary syndrome. Br J Dermatol 2005;152:98692.
  • 27
    Hahn S, Benson S, Elsenbruch S, et al. Metformin treatment of polycystic ovary syndrome improves health-related quality-of-life, emotional distress and sexuality. Hum Reprod 2006;21:192534.
  • 28
    McCook JG, Reame NE, Thatcher SS. Health-related quality of life issues in women with polycystic ovary syndrome. J Obstet Gynecol Neonatal Nurs 2005;34:1220.
  • 29
    Trent M, Austin SB, Rich M, Gordon CM. Overweight status of adolescent girls with polycystic ovary syndrome: Body mass index as mediator of quality of life. Ambul Pediatr 2005;5:10711.
  • 30
    Elsenbruch S, Benson S, Hahn S, et al. Determinants of emotional distress in women with polycystic ovary syndrome [see comment]. Hum Reprod 2006;21:10929.
  • 31
    Himelein MJ, Thatcher SS. Depression and body image among women with polycystic ovary syndrome. J Health Psychol 2006;11:61325.
  • 32
    Coffey S, Bano G, Mason HD. Health-related quality of life in women with polycystic ovary syndrome: A comparison with the general population using the Polycystic Ovary Syndrome Questionnaire (PCOSQ) and the Short Form-36 (SF-36). Gynecol Endocrinol 2006;22:806.
  • 33
    Barnard L, Ferriday D, Guenther N, et al. Quality of life and psychological well being in polycystic ovary syndrome. Hum Reprod 2007;22:227986.
  • 34
    Ching HL, Burke V, Stuckey BGA. Quality of life and psychological morbidity in women with polycystic ovary syndrome: Body mass index, age and the provision of patient information are significant modifiers. Clin Endocrinol 2007;66:3739.
  • 35
    Jedel E, Kowalski J, Stener-Victorin E. Assessment of health-related quality of life: Swedish version of polycystic ovary syndrome questionnaire. Acta Obstet Gynecol Scand 2008;87:132935.
  • 36
    Sundararaman PG, Shweta, Sridhar GR. Psychosocial aspects of women with polycystic ovary syndrome from South India. J Assoc Phys India 2008;56:9458.
  • 37
    Tan S, Hahn S, Benson S, et al. Psychological implications of infertility in women with polycystic ovary syndrome. Hum Reprod 2008;23:206471.
  • 38
    Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36). 1. Conceptual framework and item selection. Med Care 1992;30:47383.
  • 39
    Zung W, Durham NC. A Self-Rating Depression Scale. Arch Gen Psychiatry 1965;12:6370.
  • 40
    McGee HM, O'Boyle CA, Hickey A, et al. Assessing the quality of life of the individual: the SEIQoL with a healthy and a gastroenterology unit population. Psychol Med 1991;21:74959.
  • 41
    Bradley C, Todd C, Gorton T, et al. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Qual Life Res 1999;8:7991.
  • 42
    McMillan CV, Bradley C, Giannoulis M, et al. Preliminary development of a new individualised questionnaire measuring quality of life in older men with age-related hormonal decline: the A-RHDQoL. Health Qual Life Outcomes 2003;1:51.
  • 43
    Mitchell J, Bradley C. Design of an individualised measure of the impact of macular disease on quality of life (the MacDQoL). Qual Life Res 2004;13:116375.
  • 44
    The DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. Br Med J 2002;325:7469.